January 7, 2019 01:45 PM ESTUpdated January 9, 11:59 AM
News Briefing

Pos­i­tive oc­u­lar im­plant da­ta bring Al­ler­gan one step clos­er to NDA; Vivek Ra­maswamy spawns an­oth­er 'Van­t'

Natalie Grover

Reporter

→ In 2016, Brent Saun­der’s Al­ler­gan $AGN or­ches­trat­ed a string of deals af­ter its $160 bil­lion merg­er with Pfiz­er fell through thanks to Oba­ma-era tax …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

A service from the Financial Times